scholarly journals Optical coherence tomography evaluation of retinal nerve fiber layer in longitudinally extensive transverse myelitis

2011 ◽  
Vol 69 (1) ◽  
pp. 69-73 ◽  
Author(s):  
Frederico C. Moura ◽  
Danilo B. Fernandes ◽  
Samira L. Apóstolos-Pereira ◽  
Dagoberto Callegaro ◽  
Paulo E. Marchiori ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Optic Neuritis ◽  
Nerve Fiber ◽  
Retinal Nerve Fiber Layer ◽  
Transverse Myelitis ◽  
Optical Coherence ◽  
Longitudinally Extensive Transverse Myelitis ◽  
Fiber Layer ◽  
Nerve Fiber Layer ◽  
Extensive Transverse Myelitis

OBJECTIVE: To compare optical coherence tomography (OCT) measurements on the retinal nerve fiber layer (RNFL) of healthy controls and patients with longitudinally extensive transverse myelitis (LETM) without previous optic neuritis. METHOD: Twenty-six eyes from 26 patients with LETM and 26 control eyes were subjected to automated perimetry and OCT for comparison of RNFL measurements. RESULTS: The mean deviation values from perimetry were significantly lower in patients with LETM than in controls (p<0.0001). RNFL measurements in the nasal quadrant and in the 3-o'clock segment were significantly smaller in LETM eyes than in controls. (p=0.04 and p=0.006, respectively). No significantly differences in other RNFL measurements were found. CONCLUSION: Patients with LETM may present localized RNFL loss, particularly on the nasal side of the optic disc, associated with slight visual field defects, even in the absence of previous episodes of optic neuritis. These findings emphasize the fact that patients with LETM may experience attacks of subclinical optic nerve damage.

Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography

2008 ◽  
Vol 14 (7) ◽  
pp. 893-905 ◽  
Author(s):  
F Costello ◽  
W Hodge ◽  
YI Pan ◽  
E Eggenberger ◽  
S Coupland ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Optic Neuritis ◽  
Nerve Fiber ◽  
Layer Thickness ◽  
Retinal Nerve Fiber Layer ◽  
Optical Coherence ◽  
Fiber Layer ◽  
Nerve Fiber Layer ◽  
Nerve Fiber Layer Thickness ◽  
Retinal Nerve Fiber

Introduction Optic neuritis causes retinal nerve fiber layer damage, which can be quantified with optical coherence tomography. Optical coherence tomography may be used to track nerve fiber layer changes and to establish a time-dependent relationship between retinal nerve fiber layer thickness and visual function after optic neuritis. Methods This prospective case series included 78 patients with optic neuritis, who underwent optical coherence tomography and visual testing over a mean period of 28 months. The main outcome measures included comparing inter-eye differences in retinal nerve fiber layer thickness between clinically affected and non-affected eyes over time; establishing when RNFL thinning stabilized after optic neuritis; and correlating retinal nerve fiber layer thickness and visual function. Results The earliest significant inter-eye differences manifested 2-months after optic neuritis, in the temporal retinal nerve fiber layer. Inter-eye comparisons revealed significant retinal nerve fiber layer thinning in clinically affected eyes, which persisted for greater than 24 months. Retinal nerve fiber thinning manifested within 6 months and then stabilized from 7 to 12 months after optic neuritis. Regression analyses demonstrated a threshold of nerve fiber layer thickness (75μm), which predicted visual recovery after optic neuritis. Conclusions Retinal nerve fiber layer changes may be tracked and correlated with visual function within 12 months of an optic neuritis event.

Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer’s Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy

2021 ◽  
Vol 79 (1) ◽  
pp. 275-287
Author(s):  
Robert C. Sergott ◽  
Annaswamy Raji ◽  
James Kost ◽  
Cyrille Sur ◽  
Saheeda Jackson ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Optical Coherence Tomography ◽  
Nerve Fiber ◽  
Retinal Nerve Fiber Layer ◽  
Brain Atrophy ◽  
Retinal Thickness ◽  
Optical Coherence ◽  
Fiber Layer ◽  
Nerve Fiber Layer ◽  
Retinal Nerve Fiber

Background: We performed exploratory analyses of retinal thickness data from a clinical trial of the AβPP cleaving enzyme (BACE) inhibitor verubecestat in patients with Alzheimer’s disease (AD). Objective: To evaluate: 1) possible retinal thickness changes following BACE inhibition; and 2) possible association between retinal thickness and brain atrophy. Methods: Retinal thickness was measured using spectral-domain optical coherence tomography in a 78-week randomized placebo-controlled trial of verubecestat in 1,785 patients with mild-to-moderate AD. Changes from baseline in retinal pigment epithelium, macular grid retinal nerve fiber layer, central subfield retinal thickness, and macular grid volume were evaluated for verubecestat versus placebo. Correlation analyses were performed to investigate the potential association between macular grid retinal nerve fiber layer and central subfield retinal thickness with brain volumetric magnetic resonance imaging (vMRI) data at baseline, as well as correlations for changes from baseline at Week 78 in patients receiving placebo. Results: Verubecestat did not significantly alter retinal thickness during the trial compared with placebo. At baseline, mean macular grid retinal nerve fiber layer and central subfield retinal thickness were weakly but significantly correlated (Pearson’s r values≤0.23, p-values < 0.01) with vMRI of several brain regions including whole brain, hippocampus, and thalamus. At Week 78, correlations between retinal thickness and brain vMRI changes from baseline in the placebo group were small and mostly not statistically significant. Conclusion: BACE inhibition by verubecestat was not associated with adverse effects on retinal thickness in patients with mild-to-moderate AD. Correlations between retinal thickness and brain volume were observed at baseline. Trial registration: Clinicaltrials.gov NCT01739348 (registered December 3, 2012; https://clinicaltrials.gov/ct2/show/NCT01739348).

Sign in / Sign up

Export Citation Format

Share Document